Before you begin a polyclonal antibody program, it helps to know more than the name of the protein in the vial. What other proteins are present? How was the preparation characterized? And what might those findings mean when you start evaluating the antibody?
Those questions matter because immunization can generate antibodies against unintended proteins in the preparation as well as the target. Even a minor protein component may elicit antibodies that complicate specificity testing. Its relative abundance alone does not predict the strength of the immune response.
Athens Pure™ Immunogen Grade adds protein identification and lot-specific relative protein composition data, helping antibody producers assess the material before immunization
Why immunogen composition matters
Polyclonal antisera contain a mixture of antibodies. Some recognize different epitopes on the intended target; others may recognize additional proteins introduced during immunization. Unexpected binding can therefore reflect antibodies raised against an impurity, rather than cross-reactivity of a target-directed antibody. Those are different problems, even when they produce a similar assay result.
Identifying minor components early gives developers specific proteins to consider in their screening panel. It also provides context when an unexpected band or background signal appears later. The practical advantage is a more informed investigation, with fewer unknowns about the starting material.
What mass spectrometry adds to immunogen characterization
SDS-PAGE helps assess apparent molecular size and band purity. However, proteins can migrate together, and minor components may be below the sensitivity of the stain. A clean-looking gel does not identify every protein in the preparation.
LC–MS/MS complements gel analysis by identifying proteins through their peptides and estimating their relative contribution to the measured protein signal. This provides evidence for the target’s identity and information about additional proteins detected in the preparation.
For antibody producers, those identities can help guide specificity testing and provide context when unexpected binding appears.
Relative LC–MS/MS abundance is not absolute mass purity. The analysis cannot establish that all impurities are absent and does not determine native conformation. The resulting antibody still requires validation in its intended application.
How better characterization supports downstream work
Specificity testing: Identified minor proteins can help teams select relevant off-target controls before antibody screening begins.
Purification planning: If unwanted reactivities are demonstrated, their identities can inform whether additional adsorption or other purification steps should be evaluated. Composition data alone do not establish that those steps will be necessary.
Affinity ligand selection: The antigen used for antibody affinity purification also deserves scrutiny. Additional proteins in that preparation may couple to the support and retain unwanted antibody specificities. Understanding the ligand’s composition helps teams evaluate that risk.
Review the immunogen before the program begins
Planning polyclonal antibody production against a native human protein? Tell Athens Bioscience your target, quantity and intended application. We can discuss Immunogen Grade options and the characterization available for the material you are considering.